Document Detail


Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
MedLine Citation:
PMID:  22221724     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Depression is common in asthma and may be a risk factor for asthma-related morbidity and mortality. However, minimal data are available on depression treatment in asthma. Previously, we reported greater sustained depression remission and less oral corticosteroid use in asthma patients treated with citalopram.
METHOD: A 12-week randomized, double-blind, placebo-controlled, proof-of-concept trial of escitalopram was conducted in 26 outpatients with asthma requiring at least one course of oral corticosteroids in the prior 12 months and major depressive disorder (MDD) with baseline Hamilton Rating Scale for Depression (HAM-D) scores of ≥ 20.
RESULTS: Total evaluable sample (n = 25) showed significant baseline to exit reduction in HAM-D and Inventory of Depressive Symptomatology-Self Report (IDS-SR) scores, with no significant between-group differences, although the findings favored escitalopram. Depression remission on the HAM-D, from week 1 to exit, showed a trend (P = 0.06) favoring escitalopram. Relative risk for remission at week 12 was 6.5 with an estimated remission rate of 39.1% with escitalopram and 6.0% with placebo. Between-group differences in oral corticosteroid use were not significant. Changes in Asthma Control Questionnaire (ACQ) correlated significantly with changes in IDS-SR in the escitalopram, placebo, and combined sample groups (τ = 0.49-0.60, P < 0.05) and with changes in HAM-D only in placebo and combined groups (τ = 0.38-0.58, P < 0.05).
CONCLUSIONS: Medium effect sizes and a remission trend were observed favoring escitalopram over placebo on depression measures. Changes in self-reported depressive symptoms correlated with changes in asthma symptoms. A larger trial is needed to confirm the findings from this pilot study.
Authors:
E Sherwood Brown; Christina Howard; David A Khan; Thomas J Carmody
Related Documents :
1891394 - Depression in the elderly. characteristics and clinical management.
3053334 - Psychoactive drugs in the elderly: antidepressants.
15814164 - Depression and concomitant diseases in a turkish geriatric outpatient setting.
18550234 - Frontline treatment of multiple myeloma in elderly patients.
8475224 - Effect of chronic bromocriptine treatment on psychological profile of patients with prl...
10352074 - Man to man prostate cancer support groups.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Psychosomatics     Volume:  53     ISSN:  1545-7206     ISO Abbreviation:  Psychosomatics     Publication Date:    2012 Jan-Feb
Date Detail:
Created Date:  2012-01-06     Completed Date:  2012-04-11     Revised Date:  2012-04-24    
Medline Journal Info:
Nlm Unique ID:  0376506     Medline TA:  Psychosomatics     Country:  England    
Other Details:
Languages:  eng     Pagination:  75-80     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8849, USA. Sherwood.Brown@UTSouthwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adrenal Cortex Hormones / therapeutic use*
Adult
Aged
Antidepressive Agents, Second-Generation / adverse effects,  therapeutic use*
Asthma / complications,  drug therapy*,  physiopathology
Citalopram / adverse effects,  therapeutic use*
Depressive Disorder, Major / complications,  drug therapy*
Double-Blind Method
Female
Hospitalization
Humans
Male
Middle Aged
Pilot Projects
Placebos
Psychiatric Status Rating Scales
Regression Analysis
Remission Induction
Self Report
Spirometry
Time Factors
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antidepressive Agents, Second-Generation; 0/Placebos; 59729-33-8/Citalopram

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of self-reported cognitive difficulties in a national sample of long-term cancer survivor...
Next Document:  SiC formation for a solar cell passivation layer using an RF magnetron co-sputtering system.